Compare Palantir Technologies Inc (PLTR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs TransMedics Group Inc — how do they compare? Palantir Technologies Inc trades at $125.53 (market cap $318.03B), while TransMedics Group Inc trades at $71.34 (market cap $2.57B). The key difference: Palantir Technologies Inc is far larger — about 123.7× TransMedics Group Inc's market cap. Which is the better fit depends on your goals.
| PLTR | TMDX | |
|---|---|---|
Market Cap | $318.03B | $2.57B |
Sector | Technology | Technology |
52-Week High | $207.18 | $150.42 |
52-Week Low | $107.27 | $61.99 |
Enterprise Value | $310.21B | $2.97B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
